Sage Therapeutics’ Dalzanemdor Fails in Alzheimer’s, Hopes Now Rest on Huntington’s Disease Trial
Sage Therapeutics, Dalzanemdor, Alzheimer’s Disease, Huntington’s Disease, Clinical Trials, Neurodegenerative Disorders
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement
GEMMABio Secures $100M Partnership to Advance Rare Disease Gene Therapies in Brazil
GEMMABio, gene therapy, Brazil, rare diseases, $100M partnership, health ministry
RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup
RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup
Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation
Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study
Pfizer’s Former Executives Back Activist Investor Starboard’s Revamp Plan
Pfizer, Starboard Value, activist investor, Ian Read, Frank D’Amelio, Albert Bourla, pharmaceutical industry, corporate governance
Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage
Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit
Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed
Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification
Ceribell Pursues $101M Nasdaq IPO for Revolutionary Seizure-Spotting Headset
Ceribell, Seizure-Spotting Headset, Nasdaq IPO, Emergency Seizure Care, Brain-Reading Technology